Literature DB >> 16333077

Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense.

Richard J Wallace1, Barbara A Brown-Elliott, June Brown, Arnold G Steigerwalt, Leslie Hall, Gail Woods, Joann Cloud, Linda Mann, Rebecca Wilson, Christopher Crist, Kenneth C Jost, Dorothy E Byrer, Jane Tang, Jason Cooper, Elena Stamenova, Brian Campbell, Joyce Wolfe, Christine Turenne.   

Abstract

Mycobacterium peregrinum consists of two taxa: types I and II. We evaluated 43 clinical type II strains from throughout the United States. They were responsible for soft-tissue and bone infections, catheter-related infections, and possible pneumonitis. By carbohydrate utilization, they were indistinguishable from type I strains, being D-mannitol and trehalose positive. However, they had a distinct susceptibility pattern that included intermediate ciprofloxacin MICs but low clarithromycin and doxycycline MICs of < or =1 microg/ml. These features were also shared by reference isolates of Mycobacterium senegalense from African bovine cases of "farcy." By 16S rRNA gene sequencing, the type II isolates shared 100% sequence identity with M. senegalense. Partial sequencing of the type II hsp65 gene (441 bp) revealed four sequevars showing > or =98.4% identity with each other and > or =98.6% identity with the sequence of five bovine strains of M. senegalense. There was < or =97.1% identity with M. peregrinum type I isolates and other Mycobacterium fortuitum group species. Sequencing of additional gene targets including the 16S-23S rDNA internal transcribed spacer region and the rpoB gene (partial sequence) revealed a similar phylogenetic grouping. DNA-DNA hybridization showed 76 to 99% relatedness between the bovine and human strains. These studies demonstrate that type II isolates are not isolates of M. peregrinum but represent human strains of M. senegalense. This study is the first to demonstrate this species as a human pathogen. Representative human M. senegalense strains include ATCC 35755 and newly submitted strains ATCC BAA-849, ATCC BAA-850, and ATCC BAA-851.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333077      PMCID: PMC1317161          DOI: 10.1128/JCM.43.12.5925-5935.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  48 in total

1.  Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial Taxonomy.

Authors:  B A Brown; B Springer; V A Steingrube; R W Wilson; G E Pfyffer; M J Garcia; M C Menendez; B Rodriguez-Salgado; K C Jost; S H Chiu; G O Onyi; E C Böttger; R J Wallace
Journal:  Int J Syst Bacteriol       Date:  1999-10

2.  Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

Authors:  R J Wallace; G Bedsole; G Sumter; C V Sanders; L C Steele; B A Brown; J Smith; D R Graham
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov.

Authors:  S Kusunoki; T Ezaki
Journal:  Int J Syst Bacteriol       Date:  1992-04

4.  Mycobactin analysis as an aid for the identification of Mycobacterium fortuitum and Mycobacterium chelonae subspecies.

Authors:  S Bosne; V V Lévy-Frébault
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

5.  Isoelectric focusing of beta-lactamases in Mycobacterium fortuitum. Association of a single enzyme pattern with cefoxitin resistance.

Authors:  R J Wallace; D R Nash; T Udou; V A Steingrube; L C Steele; J M Swenson; V A Silcox
Journal:  Am Rev Respir Dis       Date:  1985-11

6.  Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

7.  Isoenzymes as tools to discriminate various subdivisions in the Mycobacterium fortuitum complex.

Authors:  M C Blom-Potar; H L David; N Rastogi
Journal:  Acta Leprol       Date:  1989

8.  Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.

Authors:  L C Steele; R J Wallace
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

9.  Nosocomial Mycobacterium fortuitum colonization from a contaminated ice machine.

Authors:  S Laussucq; A L Baltch; R P Smith; R W Smithwick; B J Davis; E K Desjardin; V A Silcox; A B Spellacy; R T Zeimis; H M Gruft
Journal:  Am Rev Respir Dis       Date:  1988-10

10.  Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum.

Authors:  R J Wallace; B A Brown; V A Silcox; M Tsukamura; D R Nash; L C Steele; V A Steingrube; J Smith; G Sumter; Y S Zhang
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

View more
  13 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Web-accessible database of hsp65 sequences from Mycobacterium reference strains.

Authors:  Jianli Dai; Yuansha Chen; Michael Lauzardo
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

3.  Comparison of Two Commercial Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) Systems for Identification of Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Thomas R Fritsche; Brooke J Olson; Sruthi Vasireddy; Ravikiran Vasireddy; Elena Iakhiaeva; Diana Alame; Richard J Wallace; John A Branda
Journal:  Am J Clin Pathol       Date:  2019-09-09       Impact factor: 2.493

4.  Prevalence of non-tuberculous mycobacteria among previously treated TB patients in the Gulf of Guinea, Africa.

Authors:  B D Thumamo Pokam; D Yeboah-Manu; S Ofori; P W Guemdjom; P M Teyim; L Lawson; D Amiteye; N Y Yhiler; I C Djuikoue; A E Asuquo
Journal:  IJID Reg       Date:  2022-05-14

5.  Epidemiology of Nontuberculous Mycobacteria in French Polynesia.

Authors:  Michael Phelippeau; Djaltou Aboubaker Osman; Didier Musso; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2015-12       Impact factor: 5.948

Review 6.  Mycobacterium avium in the postgenomic era.

Authors:  Christine Y Turenne; Richard Wallace; Marcel A Behr
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

7.  Mycobacterium senegalense tissue infection in a child after fish tank exposure.

Authors:  Rachel Talavlikar; Julie Carson; Bonnie Meatherill; Shalini Desai; Meenu Sharma; Cary Shandro; Gregory J Tyrrell; Susan Kuhn
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

8.  Reliable identification of mycobacterial species by PCR-restriction enzyme analysis (PRA)-hsp65 in a reference laboratory and elaboration of a sequence-based extended algorithm of PRA-hsp65 patterns.

Authors:  Erica Chimara; Lucilaine Ferrazoli; Suely Yoko Misuka Ueky; Maria Conceição Martins; Alan Mitchel Durham; Robert D Arbeit; Sylvia Cardoso Leão
Journal:  BMC Microbiol       Date:  2008-03-20       Impact factor: 3.605

9.  Draft Genome Sequence of Mycobacterium peregrinum Strain CSUR P2098.

Authors:  Shady Asmar; Nicolás Rascovan; Catherine Robert; Michel Drancourt
Journal:  Genome Announc       Date:  2015-11-05

Review 10.  Current Perspectives on Mycobacterium farcinogenes and Mycobacterium senegalense, the Causal Agents of Bovine Farcy.

Authors:  Mohamed E Hamid
Journal:  Vet Med Int       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.